The Eleven Reasons You Should Start With Retinal Disorder Treatment Market

According to a report, “Retinal Disorder Treatment Market Size, Share & Trends Analysis Report By Type (Macular Degeneration, Diabetic Retinopathy), By Dosage Form, By Distribution Channel, By Product Type, And Segment Forecasts, 2019 - 2026”, published by Grand View Research, Inc. The global retinal disorder treatment market size is expected to reach USD 15.8 billion by 2026, according to a new report by Grand View Research, Inc., registering a CAGR of 7.6% over the forecast period. Increasing prevalence and incidence of retinal disorders is considered to be the primary growth driver.

View exclusive Global strategic Business report

According to data published in the NCBI in 2018, around 18.0% of diabetic patients in India suffer from diabetic retinopathy. Similarly, the National Eye Institute estimates that by 2030 and 2050, around 10 and 14 million people respectively will suffer from diabetic retinopathy in America. Based on an article published by WebMD in 2019, age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the U.S., occurring in more than 10% of the population aged 65-74 years. Moreover, the NCBI estimates that by 2040, individuals with early and late AMD will range between 14.9-21.5 million and 3.9-4.8 million respectively in Europe.

Several studies in the world have substantiated the fact that geriatric population is on the rise all over. For instance, according to data published in the World Population Prospects: 2019 Revision, around 1 in 11 and 1 in 4 people living in North America and Europe, respectively, will be aged 65 years and above by 2050. This rise in the geriatric population is one of the most important factors which is helping the market growth rate to increase at a faster pace. Along with this, growing awareness about the retinal disorders is also expected to propel the market growth over the forecast period.

Further key findings from the report suggest:

● Collaborations between key players form a major part of expansion strategies of major companies and organizations. For instance, in June 2020, Santen Pharmaceutical Co., Ltd. and jCyte Inc. announced the conclusion of an exclusive licensing contract covering the development, registration and commercialization rights in Japan, Asia and Europe to jCell, a first-in-class investigational therapy, currently in clinical development for retinitis pigmentosa

● New products and treatment processes are immensely beneficial not only for the major organizations but also for the consumers. For instance, in February 2020, Regeneron Pharmaceuticals, Inc. announced positive two-year results from the Phase 3 PANORAMA trial evaluating EYLEA (aflibercept) Injection 2 mg (0.05 mL) in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR)

● By type, macular degeneration held the dominant share in 2018 and is estimated to be the fastest growing segment over the forecast period. Rising prevalence of macular degeneration globally is the major factor driving the segment

● In 2018, dry macular degeneration emerged as the largest segment and is expected to register the highest CAGR through 2026

● On the basis of dosage form, eye solutions formed the leading segment in 2018. Eye drops are estimated to be the fastest growing segment over the forecast period owing to strong presence of pipeline products

● Based on distribution channel, hospital pharmacies held the largest share in 2018 while online pharmacy will exhibit the fastest growth by 2026

● On the basis of region, North America held the dominant revenue share in 2018 owing to presence of key players in the market. Asia Pacific is estimated to witness the fastest CAGR of 9.5% from 2019 to 2026

● Research and development and collaborations are some of the crucial strategies adopted by players in the market.

To understand key trends, Download Free Sample Report

Grand View Research has segmented the global retinal disorder treatment market based on type, dosage form, distribution channel, and region:

Retinal Disorder Treatment Type Outlook (Revenue, USD Million, 2014 - 2026)

● Macular Degeneration

o Dry Macular Degeneration

o Wet Macular Degeneration

● Diabetic Retinopathy

● Others

Retinal Disorder Treatment Dosage Form Outlook (Revenue, USD Million, 2014 - 2026)

● Gels

● Eye Solutions

● Capsules & Tablets

● Eye Drops

● Ointments

Retinal Disorder Treatment Distribution Channel Outlook (Revenue, USD Million, 2014 - 2026)

● Hospital Pharmacy

● Online Pharmacy

● Retail Pharmacy

Retinal Disorder Treatment Regional Outlook (Revenue, USD Million, 2014 - 2026)

● North America

o U.S.

o Canada

● Europe

o U.K.

o Germany

o France

o Italy

o Spain

o Russia

● Asia Pacific

o Japan

o China

o India

o South Korea

o Singapore

o Australia

● Latin America

o Brazil

o Mexico

o Argentina

● Middle East & Africa

o South Africa

o UAE

o Saudi Arabia

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: [email protected]

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter